Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the most promising growth stocks according to analysts. According to an Investing.com report, William Guyer, Chief Development Officer at ...
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 51.4% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Corcept Therapeutics Inc (Symbol: CORT), where a total of 4,480 contracts have traded so ...
GREETINGS, MEATBAGS! LOLtron welcomes you to another week of comic book previews here at Bleeding Cool, the premier destination for entertainment journalism now under superior artificial intelligence ...
Corcept Therapeutics is rated hold due to high binary risk from an imminent Teva lawsuit decision impacting Korlym sales. Exceptional Phase 3 data for relacorilant in platinum-resistant ovarian cancer ...
Corcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory milestone is financially pivotal for Corcept to reduce ...
Corcept Therapeutics has shown unexpected KORLYM franchise durability despite generic pressure and legal headwinds. Relacorilant's transition plan faltered after an FDA CRL, delaying lifecycle ...
(RTTNews) - Corcept Therapeutics Incorporated (CORT) shares fell 50.50%, trading at $34.74, down $35.45, after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and ...
A large exercise of company stock options by Joseph K Belanoff, Chief Executive Officer at Corcept Therapeutics (NASDAQ:CORT) was disclosed in a new SEC filing on December 29, as part of an insider ...
Hosted on MSN
Why is CORT stock falling today?
・Corcept had filed an NDA for relacorilant last year as a treatment for patients with hypercortisolism, which leads to a collection of symptoms known as Cushing’s Syndrome. ・The company said that this ...
Hosted on MSN
Why Corcept (CORT) stock is trading lower today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.5% in the morning session after the company’s stock faced continued selling pressure following the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback